David Allmond
Corporate Officer/Principal at POOLBEG PHARMA PLC
Net worth: 24 289 $ as of 2024-03-30
Profile
David Allmond is currently the Chief Business Officer at Poolbeg Pharma Plc since 2023.
Prior to this, he was the Chief Executive Officer & Director at Novacyt SAS from 2021 to 2022.
He also held positions as Vice President-Global Marketing at Celgene Corp.
from 2006 to 2012, President-Europe, Middle East & Africa Regions at Aegerion Pharmaceuticals, Inc., and Chief Commercial Officer at Amryt Pharma Holdings Ltd.
from 2017 to 2020.
Additionally, he served as a Director at Myeloma UK.
Mr. Allmond received his undergraduate degree from Imperial College London.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
NOVACYT SAS
0.06% | 2022-12-30 | 43,500 ( 0.06% ) | 24 289 $ | 2024-03-30 |
David Allmond active positions
Companies | Position | Start |
---|---|---|
POOLBEG PHARMA PLC | Corporate Officer/Principal | 2023-11-30 |
Former positions of David Allmond
Companies | Position | End |
---|---|---|
NOVACYT | Chief Executive Officer | 2022-11-08 |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | 2020-08-31 |
CELGENE | Sales & Marketing | 2011-12-31 |
Myeloma UK
Myeloma UK Medical/Nursing ServicesHealth Services Myeloma UK is a charity organization that focuses on providing information and support to individuals affected by the incurable blood cancer, myeloma. If you are worried about your myeloma relapsing, Myeloma provides all the necessary information and support. The non-profit company is based in Edinburgh, UK, and was founded in 1998. The British company ensures that patients have access to the best treatments and have been transforming lives since their establishment in 1997. The organization's main goal is to give a voice to myeloma patients and their related conditions. The CEO is Rosemarie Finley. | Director/Board Member | - |
AEGERION PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Training of David Allmond
Imperial College London | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
NOVACYT | Health Technology |
POOLBEG PHARMA PLC | Health Technology |
Private companies | 4 |
---|---|
Celgene Corp.
Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aegerion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development and commercialization of therapies for patients with debilitating rare diseases. The company was founded by David I. Scheer, Gerald L. Wisler and William H. Lewis in 2005 and is headquartered in Cambridge, MA. | Health Technology |
Myeloma UK
Myeloma UK Medical/Nursing ServicesHealth Services Myeloma UK is a charity organization that focuses on providing information and support to individuals affected by the incurable blood cancer, myeloma. If you are worried about your myeloma relapsing, Myeloma provides all the necessary information and support. The non-profit company is based in Edinburgh, UK, and was founded in 1998. The British company ensures that patients have access to the best treatments and have been transforming lives since their establishment in 1997. The organization's main goal is to give a voice to myeloma patients and their related conditions. The CEO is Rosemarie Finley. | Health Services |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- David Allmond